Abstracts Archive - Page 949 of 2425 - ACR Meeting Abstracts

Abstract Number: 2863 • 2019 ACR/ARP Annual Meeting
Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
Matthew O'Dell¹, Logan Duryee ¹, Lynell Klassen ¹, James O'Dell ², Bryant England ³, Michael Duryee ¹, Geoffrey Thiele ² and Ted Mikuls ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Recently we have shown that both malondialdehyde-acetaldehyde adducts (MAA) and citrullinated proteins (CIT) are co-localized in joint and lung tissues of patients with rheumatoid…
Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino¹, Damon L Bass ², Gina Eriksson ¹, Anne Hammer ¹, Beulah Ji ³, Holly Quasny ⁴ and David Roth ⁵, ¹GlaxoSmithKline, Collegeville, ²GlaxoSmithKline, Collegeville, PA, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, ⁵GSK, Collegeville, PA
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…
Abstract Number: 2865 • 2019 ACR/ARP Annual Meeting
Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
Ginto Pottackal¹, James Travis ¹, Rosemarie Neuner ¹, Rebecca Rothwell ¹, Gregory Levin ¹, Lei Nie ¹, Jing Niu ¹, Anshu Marathe ¹ and Nikolay Nikolov ¹, ¹FDA, Silver Spring, MD
Background/Purpose: In April 2019, FDA approved the first treatment, intravenous (IV) belimumab (BEL), specifically for children 5 to 17 years of age with active, seropositive…
Abstract Number: 2866 • 2019 ACR/ARP Annual Meeting
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Amit Saxena¹, Peter Izmirly ², Rebecca Bomar ³, Shireen Golpanian ⁴, Deborah Friedman ⁵, Ruth Eisenberg ⁶, Mimi Kim ⁷ and Jill Buyon ², ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, ³New York University School of Medicine, New York, NY, New York, ⁴Miami Miller School of Medicine, Miami, ⁵New York Medical College, Valhalla, ⁶Albert Einstein College of Medicine, New York, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality, however there has been minimal information on long-term outcomes of…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 2868 • 2019 ACR/ARP Annual Meeting
Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
Nnenna Ezeh¹, Kevin Buhr², Cordellia Nguyen³, Ohoud Al Ahmed⁴, Stacy Ardoin⁵, Virginia Barton⁶, Samantha Bell⁷, Heather Brandling-Bennett⁸, Leslie Castelo-Soccio⁹, Yvonne Chiu¹⁰, Benjamin Chong¹¹, Dominic Co¹², Irene Lara-Corrales¹³, Amber Cintosun¹³, Lucia Diaz¹⁴, Scott Andrew Elman¹⁵, Esteban Fernandez Faith⁴, Maria Teresa Garcia-Romero¹⁶, Julie Grossman-Kranseler⁸, Aimee Hersh¹⁷, Marcia Hogeling¹⁸, Andrew Hudson¹⁹, Raegan Hunt²⁰, Erin Ibler¹⁰, Mariana Marques²¹, Reesa Monir²², Vikash Oza²³, Amy Paller²⁴, Elana Putterman⁹, Pamela Rodriguez-Salgado¹⁶, Jennifer Schoch²², Allison Truong¹⁸, Jason Wang²³, Lara Wine Lee⁶, Ruth Ann Vleugels¹⁵, Marisa Klein-Gitelman²⁵, Emily von-Scheven²⁶, Victoria Werth²⁷, Kaveh Ardalan²⁸and Lisa Arkin²⁹,¹University of Wisconsin School of Medicine and Public Health, Madison, WI,²Department of Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison,³University of Wisconsin School of Medicine and Public Health, Madison,⁴Department of Pediatrics, Division of Dermatology, Nationwide Children's Hospital/Ohio State University, Columbus,⁵Nationwide Children's Hospital, Columbus, OH,⁶Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston,⁷Department of Pediatrics, Division of Rheumatology, University of California at San Francisco, San Francisco,⁸Division of Dermatology; Department of Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine, Seattle,⁹Department of Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia,¹⁰Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee,¹¹University of Texas Southwestern, Dallas,¹²Department of Pediatrics, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison,¹³Department of Pediatrics, Division of Dermatology, The Hospital for Sick Children/University of Toronto, Toronto, Canada,¹⁴Department of Pediatrics, Division of Dermatology, Dell Medical School/Dell Children's Hospital, Austin, Texas,¹⁵Department of Dermatology, Boston's Children Hospital/Harvard Medical School, Boston,¹⁶Department of Dermatology, National Institute for Pediatrics, Mexico City, Mexico,¹⁷University of Utah, Salt Lake City, UT,¹⁸Department of Dermatology, University of California at Los Angeles, Los Angeles,¹⁹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas,²⁰Departments of Pediatrics and Dermatology, Texas Children's Hospital, Houston, Texas,²¹Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,²²Department of Dermatology, University of Florida School of Medicine, Gainesville,²³Departments of Pediatrics and Dermatology, New York University School of Medicine, New York,²⁴Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,²⁵Department of Pediatrics, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital, Chicago,²⁶University of California San Francisco, San Francisco,²⁷Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA,²⁸Division of Pediatric Rheumatology, Department of Pediatrics, Northwestern University, Chicago, Illinois,²⁹Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Background/Purpose: DLE is a rare, disfiguring disorder in children. Small retrospective studies suggest 20-25% of patients progress to SLE. Progression risk factors are poorly understood,…
Abstract Number: 2869 • 2019 ACR/ARP Annual Meeting
Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
Jessica Neely ¹, Susan Kim ¹, Hugh Sturrock ² and Julia Shalen², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco
Background/Purpose: Factors associated with diagnostic delay in Juvenile Dermatomyositis (JDM) are not known. We hypothesized that limited access to pediatric rheumatologists can lead to delay…
Abstract Number: 2870 • 2019 ACR/ARP Annual Meeting
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Felice Rivellese¹, Gloria Lliso-Ribera ², Alessandra Nerviani ¹, Frances humby ³ and Costantino Pitzalis ¹, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: Synovial B cell aggregates in patients with early Rheumatoid Arthritis (RA) have been associated with disease severity and radiographic progression. Here, we analysed the…
Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Xanthe ME Matthijssen¹, Ellis Niemantsverdriet ², Thomas Huizinga ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
Abstract Number: 2872 • 2019 ACR/ARP Annual Meeting
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Ali Yazdanyar¹, Anthony Donato ², Kathleen McElwee ³, Mary Chester Wasko ⁴ and Michael Ward ⁵, ¹Lehigh Valley Hospital- Cedar Crest, Allentown, PA, ²Reading Hospital, PA, Reading, ³Reading Hospital, Reading, PA, ⁴Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁵NIAMS, Bethesda, MD
Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or…
Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson¹, Olafur Palsson ², Mar Kristjansson ³, Petur S Gunnarsson ⁴, Gerdur Grondal ⁵, Bjorn Gudbjornsson ⁶ and Thorvardur J Love ⁷, ¹Department of Medicine, Landspitali, Reykjavík, Iceland, ²Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, ³Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, ⁴Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, ⁵Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
Abstract Number: 2874 • 2019 ACR/ARP Annual Meeting
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Ann Madsen ⁴, Jamie Geier ⁴, Jose L. Rivas ⁵, Alina Onofrei ⁶, Christine Barr ⁶, Dimitrios Pappas ⁷, Heather Litman ⁶, Kimberly Dandreo ⁶, Andrea Shapiro ⁸, Carol Connell ⁹ and Arthur Kavanaugh ¹⁰, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer SLU, Madrid, Spain, ⁶Corrona, LLC, Waltham, MA, ⁷Columbia University, New York, NY, ⁸Pfizer Inc, Peapack, NJ, ⁹Pfizer Inc, Groton, CT, ¹⁰University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…
Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Mark Genovese¹, Kenneth Kalunian ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, YingMeei Tan ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
Abstract Number: 2876 • 2019 ACR/ARP Annual Meeting
Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients
Elsa Vieira-Sousa¹, Pedro Alves ², Ana Maria Rodrigues ³, Filipa Teixeira ⁴, José Tavares-Costa ⁵, Alexandra Bernardo ⁶, Sofia Pimenta ⁶, Fernando Pimentel-Santos ⁷, João Lagoas Gomes ⁸, Renata Aguiar ⁹, Patrícia Pinto ¹⁰, Taciana Videira ¹⁰, Cristina Catita ¹¹, Helena Santos ¹², Joana Borges ¹³, Graça Sequeira ¹⁴, Célia Ribeiro ¹⁴, Lídia Teixeira ¹⁵, Pedro Ávila-Ribeiro ¹⁶, Fernando M Martins ¹⁷, Helena Canhão ¹⁸, Ruy M Ribeiro ¹⁹ and João Eurico Fonseca ¹⁶, ¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²Radiology Department, CHLC, Lisbon, Portugal, ³Rheumatology Unit, , HSEIT, Ilha Terceira, Açores e FMUL, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁴Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ⁵ULSAM, Ponte de Lima, Portugal, ⁶Rheumatology Department, CHSJ, Porto, Portugal, ⁷CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ⁸Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ⁹Rheumatology Department, CHBV, Aveiro, Portugal, ¹⁰Rheumatology Department, CHVNG, Vila Nova de Gaia, Portugal, ¹¹Hospital Particular do Algarve, Faro, Portugal, ¹²Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ¹³Instituto Português de Reumatologia, Lisbon, Portugal, ¹⁴Rheumatology Unit, CHA, Faro, Portugal, ¹⁵Rheumatology Department, HGO, Almada, Portugal, ¹⁶Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ¹⁷Portuguese Society of Rheumatology, Lisbon, Portugal, ¹⁸CEDOC, EpiDoC Unit, NOVA Medical School, Lisbon, Lisbon, Portugal, ¹⁹Laboratório de Biomatemática, FMUL, Lisbon, Portugal
Background/Purpose: Psoriatic arthritis (PsA) dactylitis is associated with an increased risk of erosions and higher disease activity. Dactylitis treatment strategies are however controversial due to…
Abstract Number: 2877 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Kim Papp¹, Melinda Gooderham ², Akimichi Morita ³, Alan Kivitz ⁴, Ranjeeta Sinvhal ⁵, Andrew Topp ⁵, Graham Heap ⁵, Ann Eldred ⁵ and Philip Mease ⁶, ¹K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada, ²2School of Medicine, Queen’s University, Kingston, ON and Skin Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].